| Literature DB >> 29988049 |
Donghoon Kim1,2, Je Min Yoo3, Heehong Hwang1,4, Junghee Lee5, Su Hyun Lee1,2, Seung Pil Yun1,2,6, Myung Jin Park3, MinJun Lee3, Seulah Choi1, Sang Ho Kwon1, Saebom Lee1,2, Seung-Hwan Kwon1,2, Sangjune Kim1,2, Yong Joo Park7, Misaki Kinoshita8, Young-Ho Lee8, Seokmin Shin3, Seung R Paik9, Sung Joong Lee4, Seulki Lee7,10, Byung Hee Hong11,12, Han Seok Ko13,14,15,16.
Abstract
Though emerging evidence indicates that the pathogenesis of Parkinson's disease is strongly correlated to the accumulation1,2 and transmission3,4 of α-synuclein (α-syn) aggregates in the midbrain, no anti-aggregation agents have been successful at treating the disease in the clinic. Here, we show that graphene quantum dots (GQDs) inhibit fibrillization of α-syn and interact directly with mature fibrils, triggering their disaggregation. Moreover, GQDs can rescue neuronal death and synaptic loss, reduce Lewy body and Lewy neurite formation, ameliorate mitochondrial dysfunctions, and prevent neuron-to-neuron transmission of α-syn pathology provoked by α-syn preformed fibrils5,6. We observe, in vivo, that GQDs penetrate the blood-brain barrier and protect against dopamine neuron loss induced by α-syn preformed fibrils, Lewy body/Lewy neurite pathology and behavioural deficits.Entities:
Mesh：
Substances：
Year: 2018 PMID： 29988049 PMCID： PMC6351226 DOI： 10.1038/s41565-018-0179-y
Source DB: PubMed Journal: Nat Nanotechnol ISSN： 1748-3387 Impact factor: 39.213